All the news Showing 10 of 37 articles from: Hepatocellular carcinoma (HCC)Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Aspirin use associated with lower risk of liver cancer Liz Highleyman / 13 November 2018 Taking aspirin about twice a week for five years or more may reduce the risk of developing hepatocellular carcinoma (HCC) by about half, according to research presented this week at the AASLD Liver ... US FDA approves pembrolizumab immunotherapy for liver cancer Liz Highleyman / 12 November 2018 The US Food and Drug Administration last week granted accelerated approval for pembrolizumab (Keytruda), an immunotherapy drug known as a checkpoint inhibitor, for people with hepatocellular carcinoma (HCC). Over years or decades chronic hepatitis B ... What support do people with liver cirrhosis and their families need? Keith Alcorn / 09 October 2018 People with liver cirrhosis and their families need more information about their condition and prognosis and greater access to palliative care, a systematic review of studies on the needs of people with cirrhosis ... Local therapy with sorafenib does not improve liver cancer survival Liz Highleyman / 23 April 2018 Combining sorafenib (Nexavar) with internal radiation therapy or transarterial chemoembolization did not improve overall survival for people with liver cancer, but it did appear to help certain groups of patients, according to research presented ... Secondary liver cancer after colorectal cancer more common in people with chronic hepatitis B Keith Alcorn / 22 January 2018 The spread of cancer from the bowel to the liver – metastasis – is more likely to occur in people with chronic hepatitis B infection, a Chinese study published in ... Nivolumab improves outcomes in liver cancer study Liz Highleyman / 13 November 2017 Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumour size or disease stabilisation in people with hepatocellular carcinoma (HCC) in the CheckMate ... Curing hepatitis C with DAAs linked to 71% reduction in liver cancer Liz Highleyman / 30 October 2017 People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, ... Nivolumab increases survival for people with advanced liver cancer Liz Highleyman / 22 April 2017 The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well tolerated as a treatment for advanced liver cancer that did not respond to standard treatment, researchers reported on ... Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies Liz Highleyman / 21 April 2017 People with hepatitis C who take treatment with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher ... Statins reduce risk of decompensation for people with HCV- and HBV-related cirrhosis Michael Carter / 18 April 2017 Treatment with statins reduces the risk of decompensated liver disease for people with cirrhosis caused by hepatitis B virus (HBV) and hepatitis C virus (HCV), investigators from Taiwan report in the online edition ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive